Therapeutic Solutions International (TSOI) 10-Q/A 24 Aug 20 2020 Q2 Quarterly report (amended) Financial data

Document and Entity Information

Document and Entity Information - $ / shares	Aug. 19, 2020	Jun. 30, 2020
Details
Registrant CIK		0001419051
Fiscal Year End		--12-31
Document Type		10-Q/A
Document Quarterly Report		true
Document Period End Date		Jun. 30, 2020
Document Transition Report		false
Entity File Number		000-54554
Entity Registrant Name		THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.
Entity Incorporation, State or Country Code		NV
Entity Tax Identification Number		45-1226465
Entity Address, Address Line One		4093 Oceanside Boulevard, Suite B
Entity Address, City or Town		Oceanside
Entity Address, State or Province		CA
Entity Address, Postal Zip Code		92056
Entity Address, Address Description		Address of principal executive offices, including zip code
City Area Code		760
Local Phone Number		295-7208
Phone Fax Number Description		Registrant’s telephone number, including area code
Entity Current Reporting Status		Yes
Entity Interactive Data Current		Yes
Entity Filer Category		Non-accelerated Filer
Entity Small Business		true
Entity Emerging Growth Company		false
Entity Shell Company		false
Entity Common Stock, Shares Outstanding	1,987,355,997
Entity Listing, Par Value Per Share	$ 0.001
Amendment Flag		false
Document Fiscal Year Focus		2020
Document Fiscal Period Focus		Q2

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Current Assets
Cash and cash equivalents	$ 31,741	$ 26,410
Restricted cash	10,202	10,187
Accounts receivable	4,233	2,904
Inventory	3,838	5,180
Prepaid expenses and other current assets	74,325	89,379
Right-of-use asset	65,384	5,619
Total current assets	189,723	139,679
Property and equipment, net	5,383	0
Assets, Noncurrent	151,580	171,322
Total assets	346,686	311,001
Current liabilities:
Accounts payable	329,400	324,936
Accounts payable-related parties	7,222	12,715
Accrued expenses and other current liabilities	512,624	505,072
Lease liability	20,240	5,619
Convertible notes payable, net of discount of $82,800 and $105,525, at June 30, 2020 and December 31, 2019, respectively	21,200	38,475
Notes payable-related parties, net	954,611	937,528
Derivative Liability, Current	187,968	521,700
Total current liabilities	2,033,265	2,346,045
LONG TERM LIABILITIES
Notes payable, net of current portion	7,145	0
Lease liability, net of current portion	45,144	0
TOTAL LIABILITIES	2,085,554	2,346,045
Commitments and contingencies	0	0
Shareholders' deficit:
Preferred shares	0	0
Common shares	1,947,439	1,614,628
Additional paid-in capital	6,003,461	5,183,228
Accumulated deficit	(9,689,768)	(8,832,900)
Total shareholders' deficit	(1,738,868)	(2,035,044)
Total liabilities and shareholders' deficit	$ 346,686	$ 311,001

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) - Parenthetical - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Details
Debt Instrument, Unamortized Discount, Current	$ 82,800	$ 105,525
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	2,500,000,000	2,500,000,000
Common Stock, Shares, Issued	1,947,438,492	1,614,627,811
Common Stock, Shares, Outstanding	1,947,438,492	1,614,627,811

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2018	Jun. 30, 2020	Jun. 30, 2019
Details
Net sales	$ 14,021	$ 8,931	$ 33,535	$ 11,395
Cost of goods sold	2,463	1,036	5,953	1,182
Gross profit	11,558	7,895	27,582	10,213
Operating Expenses
General and administrative	18,772	20,138	34,203	33,621
Salaries, wages, and related costs	55,243	98,982	108,413	205,388
Officer's director's compensation	151,500	0	151,500	225,000
Consulting fees	34,041	50,966	71,260	84,351
Legal and professional fees	94,428	25,809	127,008	82,443
Research and development	329,772	6,232	329,772	6,232
Total operating expenses	683,756	202,127	822,156	637,035
Operating Income (Loss)	(672,198)	(194,232)	(794,574)	(626,822)
Other income (expense):
Loss on derivatives liabilities	(82,493)	(19,133)	(103,248)	(227,060)
Change in fair value of derivative liabilities	(18,126)	88,020	218,276	440,891
Interest expense	(94,987)	(102,675)	(156,122)	(190,175)
Other income	(21,200)	0	(21,200)	0
Total other income (expense)	(216,806)	(33,788)	(62,294)	23,656
Net Income (Loss)	$ (889,004)	$ (228,020)	$ (856,868)	$ (603,166)
Basic and diluted net loss per common share	$ 0	$ 0	$ 0	$ 0
Basic and diluted weighted-average common shares outstanding	1,723,008,195	1,144,167,799	1,672,290,253	1,117,620,490

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Shareholders' Deficit (Unaudited) - USD ($)	Common Stock	Additional Paid-in Capital	Retained Earnings	Total
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2018	$ 1,011,063	$ 4,314,047	$ (7,135,578)	$ (1,810,468)
Shares, Outstanding, Beginning Balance at Dec. 31, 2018	1,011,063,182
Stock Issued During Period, Value, Issued for Services	$ 70,000	229,000	0	299,000
Stock Issued During Period, Shares, Issued for Services	70,000,000
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments	$ 105,980	340,606	0	446,586
Stock Issued During Period, Shares, Conversion of Convertible Securities	105,980,405
Common stock issued for a license, Value	$ 95,970	57,582	0	153,552
Common stock issued for a license, Shares	95,970,000
Stock Issued During Period, Value, New Issues	$ 12,000	6,000	0	18,000
Stock Issued During Period, Shares, New Issues	12,000,000
Beneficial conversion feature on note payable	$ 0	12,500	0	12,500
Net Income (Loss)	$ 0	0	(603,166)	(603,166)
Shares, Outstanding, Ending Balance at Jun. 30, 2019	1,295,013,587
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Jun. 30, 2019	$ 1,295,013	4,959,735	(7,738,744)	(1,483,996)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Mar. 31, 2019	$ 1,101,102	4,709,028	(7,510,724)	(1,700,594)
Shares, Outstanding, Beginning Balance at Mar. 31, 2019	1,101,102,071
Stock Issued During Period, Value, Issued for Services	$ 15,000	9,000	0	24,000
Stock Issued During Period, Shares, Issued for Services	15,000,000
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments	$ 70,941	165,625	0	236,566
Stock Issued During Period, Shares, Conversion of Convertible Securities	70,941,516
Common stock issued for a license, Value	$ 95,970	57,582	0	153,552
Common stock issued for a license, Shares	95,970,000
Stock Issued During Period, Value, New Issues	$ 12,000	6,000	0	18,000
Stock Issued During Period, Shares, New Issues	12,000,000
Beneficial conversion feature on note payable	$ 0	12,500	0	12,500
Net Income (Loss)	$ 0	0	(228,020)	(228,020)
Shares, Outstanding, Ending Balance at Jun. 30, 2019	1,295,013,587
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Jun. 30, 2019	$ 1,295,013	4,959,735	(7,738,744)	(1,483,996)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2019	$ 1,614,628	5,183,228	(8,832,900)	(2,035,044)
Shares, Outstanding, Beginning Balance at Dec. 31, 2019	1,614,627,811
Stock Issued During Period, Value, Issued for Services	$ 156,000	413,700	0	569,700
Stock Issued During Period, Shares, Issued for Services	156,000,000
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments	$ 142,450	10,190	0	152,640
Stock Issued During Period, Shares, Conversion of Convertible Securities	142,449,554
Stock Issued During Period, Value, New Issues	$ 16,179	40,821	0	57,000
Stock Issued During Period, Shares, New Issues	16,179,309
Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture	$ 18,182	41,818	0	60,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	18,181,818
Relief of derivative liabilities, Value	$ 0	313,704	0	313,704
Relief of derivative liabilities, Shares	0
Net Income (Loss)	$ 0	0	(856,868)	(856,868)
Shares, Outstanding, Ending Balance at Jun. 30, 2020	1,947,438,492
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Jun. 30, 2020	$ 1,947,439	6,003,461	(9,689,768)	(1,760,686)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Mar. 31, 2020	$ 1,656,544	5,206,268	(8,800,764)	(1,937,952)
Shares, Outstanding, Beginning Balance at Mar. 31, 2020	1,656,544,032
Stock Issued During Period, Value, Issued for Services	$ 156,000	413,700	0	569,700
Stock Issued During Period, Shares, Issued for Services	156,000,000
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments	$ 100,534	20,106	0	120,640
Stock Issued During Period, Shares, Conversion of Convertible Securities	100,533,333
Stock Issued During Period, Value, New Issues	$ 16,179	40,821	0	57,000
Stock Issued During Period, Shares, New Issues	16,179,309
Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture	$ 18,182	41,818	0	60,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	18,181,818
Relief of derivative liabilities, Value	$ 0	280,748	0	280,748
Relief of derivative liabilities, Shares	0
Net Income (Loss)	$ 0	0	(889,004)	(889,004)
Shares, Outstanding, Ending Balance at Jun. 30, 2020	1,947,438,492
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Jun. 30, 2020	$ 1,947,439	$ 6,003,461	$ (9,689,768)	$ (1,760,686)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net Income (Loss)	$ (856,868)	$ (603,166)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation to consultants	100,200	74,000
Stock based compensation to related parties	529,500	225,000
Loss on derivative liabilities	103,248	227,060
Change in fair value of derivatives liabilities	(218,276)	(440,891)
Amortization of debt discount	131,663	157,902
Patent amortization	3,296	0
Depreciation	65	0
Changes in operating assets and liabilities:
Accounts receivable	(1,329)	(1,475)
Inventory	1,342	0
Prepaid expenses and other current assets	31,500	1,100
Right-to-use asset	(59,765)	(22,116)
Accounts payable	4,465	1,658
Accounts payable - related parties	(5,493)	0
Accrued expenses and other current liabilities	22,199	186,504
Lease liability	59,764	22,116
Net cash used in operating activities	(154,489)	(172,308)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(5,448)	0
Net cash used in investing activities	(5,448)	0
Cash flows from financing activities:
Payments on notes payable to related party	(1,196)	(1,505)
Proceeds from notes payable to related party	0	25,000
Proceeds from convertible notes payable	95,000	115,000
Proceeds from notes payable	14,479	0
Proceeds from sale of common stock	57,000	18,000
Net cash provided by financing activities	165,283	156,495
Net increase (decrease) in cash	5,346	(15,813)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance	36,597	32,570
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance	41,943	16,757
Supplemental disclosure of cash flow information
Cash paid for interest	1,250	1,980
Income Taxes Paid	0	0
Non-cash investing and financing transactions:
Original issuance discount on convertible notes payable	9,000	12,000
Debt discount recorded in connection with derivative liability	95,000	115,000
Common stock issued in conversion of convertible notes payable and interest	466,344	446,586
Beneficial conversion feature on note payable	0	12,500
Common stock issued in payment of license agreement	0	153,552
Formalization of accrued salary into related party note	0	0
Accrued interest added to principal	13,341	0
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 41,943	$ 16,757

Note 1 - Organization and Busin

Note 1 - Organization and Business Description	6 Months Ended
	Jun. 30, 2020
Notes
Note 1 - Organization and Business Description	Note 1 – Organization and Business Description Therapeutic Solutions International, Inc. (“TSOI” or the “Company”) was organized August 6, 2007 under the name Friendly Auto Dealers, Inc., under the laws of the State of Nevada. In the first quarter of 2011, the Company changed its name from Friendly Auto Dealers, Inc. to Therapeutic Solutions International, Inc., and acquired Splint Decisions, Inc., a California corporation. Currently, the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. Activating one’s immune system is now an accepted method to cure certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders, and allergic reactions. TSI is developing a range of immune-modulatory agents to target certain cancers and diseases, and for daily health. Nutraceutical Division Cellular Division The stem cell licensed, termed “JadiCell” is unique in that it possesses features of mesenchymal stem cells, however, outperforms these cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and neurogenic ability. Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment to enhance receptivity of regenerative cells such as stem cells. The Company announced recently submission of a publication providing preclinical data which supports repositioning of its Cancer Immunotherapy StemVacs™ as a candidate for treatment of COVID-19. StemVacs™ is based on activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body’s “Natural Killer” cells. Natural killer cells are the most potent cell type in the body in terms of killing viruses. Unfortunately, natural killer cells also produce chemicals called cytokines which at high concentrations can be lethal. The current data suggests that StemVacs™ can activate natural killer cells while at the same time suppressing lung inflammation. This dual mechanism of action makes StemVacs™ a promising candidate for treatment of coronavirus. Management does not expect existing cash as of June 30, 2020 to be sufficient to fund the Company’s operations for at least twelve months from the issuance date of these financial statements. These financial statements have been prepared on a going concern basis which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of June 30, 2020, the Company has incurred losses totaling $9.7 million since inception, has not yet generated material revenue from operations, and will require additional funds to maintain its operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company’s ability to continue as a going concern is dependent upon its ability to generate future profitable operations and obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to finance operating costs over the next twelve months through its existing financial resources and we may also raise additional capital through equity offerings, debt financings, collaborations and/or licensing arrangements. If adequate funds are not available on acceptable terms, we may be required to delay, reduce the scope of, or curtail, our operations. The accompanying consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Notes
Note 2 - Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission (SEC) Regulation S-X, and should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2019, included in the Company’s Annual Report on Form 10-K filed with the SEC on May 21, 2020. The accompanying unaudited condensed consolidated financial statements include the accounts of TSOI and its subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation. The unaudited condensed consolidated financial statements contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the balances and results for the interim period included herein. The results of operations for the three and six months ended June 30, 2020 and 2019 are not necessarily indicative of the results to be expected for the full year or any future interim periods. The accompanying condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated balance sheet at December 31, 2019, contained in the above referenced Form 10-K. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Revenue Recognition The Company recognizes revenue in accordance with ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue: 1) 2) 3) 4) 5) ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service. Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2020 and 2019 as disclosed in Note 5, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $187,968 and $521,700 at June 30, 2020 and December 31, 2019, respectively. Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of June 30, 2020, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: The following is the change in derivative liability for the six months ended June 30, 2020: Balance- December 31, 2019 $ 521,700 Issuance of new derivative liabilities 198,248 Conversions to paid-in capital (313,704) Change in fair market value of derivative liabilities (218,276) Balance- June 30, 2020 $ 187,968 Use of Estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates. Net Income (Loss) Per Share Basic income (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted income (loss) per share is computed similar to basic income (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. In periods in which a net loss is incurred, basic and diluted loss per share are the same, and additional potential common shares are excluded as their effect would be antidilutive. For the periods ended June 30, 2020 and 2019, a total of 47,358,833 and 876,393,993, respectively, potential common shares, consisting of shares underlying outstanding convertible notes payable were excluded as their inclusion would be antidilutive due to the net loss during the period. Property and Equipment Property and equipment are recorded at cost, less accumulated depreciation. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is calculated using the straight-line method over the term of the agreement. Depreciation expense for the six months ended June 30, 2020 and 2019 was $65 and $0, respectively. Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the six months ended June 30, 2020 and 2019 was $3,296 and $0, respectively. Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value. Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $329,772 and $6,232 for the six months ended June 30, 2020 and 2019, respectively. Income Taxes The Company accounts for income taxes under ASC 740 "Income Taxes," which codified SFAS 109, "Accounting for Income Taxes" and FIN 48 “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees. Leases In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. The Company recorded a Right-of-use asset of $65,384 and a Lease Liability of $65,384 as of June 30, 2020. Recent Accounting Pronouncements In December 2019, the FASB issued guidance that simplifies the accounting for income taxes by removing certain exceptions in existing guidance and improves consistency in application by clarifying and amending existing guidance. This guidance is effective for annual periods beginning after December 15, 2020, and interim periods within those annual periods, where the transition method varies depending upon the specific amendment. Early adoption is permitted, including adoption in any interim period. An entity that elects to early adopt the amendments in an interim period should reflect any adjustments as of the beginning of the annual period that includes that interim period, and all amendments must be adopted in the same period. The Company has reviewed the provisions of the new standard, but it is not expected to have a significant impact on the Company. In January 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-01, "Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying the Interactions between Topic 321, Topic 323, and Topic 815", which clarifies the interaction of the accounting for equity securities under Topic 321 and investments accounted for under the equity method of accounting under Topic 323, and the accounting for certain forward contracts and purchased options accounted for under Topic 815. This guidance is effective for the Company for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Early adoption is permitted. The Company has reviewed the provisions of the new standard, but it is not expected to have a significant impact on the Company.

Note 3 - Restricted Cash

Note 3 - Restricted Cash	6 Months Ended
	Jun. 30, 2020
Notes
Note 3 - Restricted Cash	Note 3 - Restricted Cash Included in cash and non-cash equivalents is a $10,000 certificate of deposit with an annual interest rate of 0.6%. This certificate matures on June 17, 2021 and is used as collateral for a Company credit card, pursuant to a security agreement dated June 20, 2011.

Note 4 - Property and Equipment

Note 4 - Property and Equipment	6 Months Ended
	Jun. 30, 2020
Notes
Note 4 - Property and Equipment	Note 4 – Property and Equipment Fixed assets consisted of the following: June 30, 2020 December 31, 2019 Computer hardware $ 10,747 $ 10,747 Office furniture and equipment 9,087 3,639 Shipping and other equipment 1,575 1,575 Total 21,409 15,961 Accumulated depreciation (16,026) (15,961) Property and equipment, net $ 5,383 $ - Depreciation expense for the six months ended June 30, 2020 and 2019 was $65 and $0, respectively.

Note 5 - Other Assets

Note 5 - Other Assets	6 Months Ended
	Jun. 30, 2020
Notes
Note 5 - Other Assets	Note 5 – Other Assets Other assets consist of the following: June 30, 2020 December 31, 2019 Prepaid consulting $ 3,792 $ 20,238 Deposit 4,123 4,123 Licenses, net 143,665 146,961 Total $ 151,580 $ 171,322 Prepaid consulting agreements are for one to two years and are expensed monthly over the term of the agreement. The net licenses amount consists of the following: June 30, 2020 December 31, 2019 License $ 153,552 $ 153,552 Accumulated amortization (9,887) (6,591) Licenses, net $ 143,665 $ 146,961

Note 6 - Notes Payable-Related

Note 6 - Notes Payable-Related Party	6 Months Ended
	Jun. 30, 2020
Notes
Note 6 - Notes Payable-Related Party	Note 6 - Notes Payable-Related Party At June 30, 2020 and December 31, 2019, the Company has unsecured interest-bearing demand notes outstanding to certain officers and directors amounting to $954,611 and $937,528, respectively. Interest accrued on these notes during the six months ended June 30, 2020 and 2019 was $13,341 and $7,936, respectively. Of these, $251,000 are convertible into common stock at prices ranging from $0.004 and $0.005.

Note 7 - Convertible Notes Paya

Note 7 - Convertible Notes Payable	6 Months Ended
	Jun. 30, 2020
Notes
Note 7 - Convertible Notes Payable	Note 7 – Convertible Notes Payable On February 4, 2020, April 27, 2020, and June 5, 2020, the Company entered into one $33,000, one $28,000, and one $43,000 convertible promissory notes with a third party for which the proceeds were used for operations. The Company received net proceeds of $95,000, and a $9,000 original issuance discount was recorded. The convertible promissory notes incur interest at 12% per annum and mature on dates ranging from February 3, 2021 to June 5, 2021. The convertible promissory notes are convertible to shares of the Company's common stock 180 days after issuance. The conversion price per share is equal to 61% of the average of the three (3) lowest trading prices of the Company's common stock during the fifteen (15) trading days immediately preceding the applicable conversion date. The trading price is defined within the agreement as the closing bid price on the applicable trading market. The Company has the option to prepay the convertible notes in the first 180 days from closing subject to prepayment penalties ranging from 120% to 145% of principal balance plus interest, depending upon the date of prepayment. The convertible promissory notes include various default provisions for which the default interest rate increases to 22% per annum with the outstanding principal and accrued interest increasing by 150%. The Company was required to reserve at June 30, 2020 a total of 600,463,381 common shares in connection with these promissory notes. Derivative liabilities These convertible promissory notes are convertible into a variable number of shares of common stock for which there is not a floor to the number of common stock shares we might be required to issue. Based on the requirements of ASC 815 Derivatives and Hedging, the conversion feature represented an embedded derivative that is required to be bifurcated and accounted for as a separate derivative liability. The derivative liability is originally recorded at its estimated fair value and is required to be revalued at each conversion event and reporting period. Changes in the derivative liability fair value are reported in operating results each reporting period. The company uses the Black-Scholes option pricing model for the valuation of its derivative liabilities as further discussed below. There are no material differences between using the Black-Scholes option pricing model for these estimates as compared to the Binomial Lattice model. For the three notes issued during the six months ended June 30, 2020, the Company valued the conversion features on the date of issuance resulting in initial liabilities totaling $198,248. Since the fair value of the derivative was in excess of the proceeds received, a full discount to convertible notes payable and a day one loss on derivative liabilities of $103,248 was recorded during the six months ended June 30, 2020. The Company valued the conversion feature using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.0008 to $0.0012, the closing stock price of the Company's common stock on the dates of valuation ranging from $0.0023 to $0.0033, an expected dividend yield of 0%, expected volatilities ranging from 239%-255%, risk-free interest rate ranging from 0.17% to 1.48%, and an expected term of one year. At December 31, 2019, the Company had existing derivative liabilities of $521,700 related to three convertible notes totaling $144,000. During the six months ended June 30, 2020, these convertible notes plus their accrued interest were fully converted into 142,449,554 shares of common stock. At each conversion date, the Company recalculated the value of the derivative liability associated with the convertible note recording a gain (loss) in connection with the change in fair market value. In addition, the pro-rata portion of the derivative liability as compared to the portion of the convertible note converted was reclassed to additional paid-in capital. During the six months ended June 30, 2020, the Company recorded $313,704 to additional paid-in capital. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: conversion prices ranging from $0.00055 to $0.0012, the closing stock price of the Company's common stock on the dates of valuation ranging from $0.001 to $0.010, an expected dividend yield of 0%, expected volatility ranging from 197% to 305%, risk-free interest rates ranging from 0.13% to 0.89%, and expected terms ranging from 0.07 to 0.49 years. On June 30, 2020, the derivative liabilities on the remaining three convertible notes were revalued at $187,968 resulting in a gain of $218,276 for the six months ended June 30, 2020 related to the change in fair value of the derivative liabilities. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following assumptions: exercise price of $0.0076, the closing stock price of the Company's common stock on the date of valuation of $0.0022, an expected dividend yield of 0%, expected volatility ranging from 256% to 300%, risk-free interest rate of 0.16%, and an expected term ranging from 0.60 to 0.93 years. The Company amortizes the discounts over the term of the convertible promissory notes using the straight-line method which is similar to the effective interest method. During the six months ended June 30, 2020 and 2019, the Company amortized $126,724 and $157,902 to interest expense, respectively. As of June 30, 2020, discounts of $82,500 remained for which will be amortized through June 4, 2021.

Note 8 - Equity

Note 8 - Equity	6 Months Ended
	Jun. 30, 2020
Notes
Note 8 - Equity	Note 8 – Equity Our authorized capital stock consists of an aggregate of 2,505,000,000 shares, comprised of 2,500,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, which may be issued in various series from time to time and the rights, preferences, privileges and restrictions of which shall be established by our board of directors. As of June 30, 2020, we have 1,947,438,492 shares of common stock and no preferred shares issued and outstanding. On March 2, 2020, we issued 8,333,333 shares of common stock for the partial conversion of $10,000 for a convertible note dated August 28, 2019. On March 12, 2020, we issued 11,764,706 shares of common stock for the partial conversion of $10,000 for convertible note dated August 28, 2019. On March 26, 2020, we issued 21,818,182 shares of common stock for the partial conversion of $12,000 for convertible note dated August 28, 2019. On May 29, 2020, we issued 10,000,000 shares of common stock for the partial conversion of $12,000 for convertible note dated August 28, 2019. On June 2, 2020, we issued 12,500,000 shares of common stock for the partial conversion of $15,000 for convertible note dated August 28, 2019. On June 3, 2020, we issued 19,733,333 shares of common stock for the partial conversion of $23,680 for convertible note dated August 28, 2019. On June 4, 2020, we issued 24,733,333 shares of common stock for the complete conversion of $29,680 for convertible note dated October 30, 2019. On June 4, 2020, we issued 5,000,000 shares of common stock, valued at $0.0023 per share, for consulting services. On June 4, 2020 we issued 70,000,000 shares of common stock, valued at $0.0023 each to three officers and one director of the Company under a Restricted Stock Award. On June 8, 2020, we issued 10,000,000 shares of common stock, valued at $0.0033 per share, for consulting services. On June 9, 2020, the Company settled an accrual of wages with Timothy G. Dixon with a convertible note payable of $60,000 with interest at 5% per annum. On June 9, 2020, we issued 18,181,818 shares of common stock for the complete conversion of $60,000 for convertible note dated June 9, 2020. On June 11, 2020 we issued 40,000,000 shares of common stock, valued at $0.0046 each to three officers and one director of the Company under a Restricted Stock Award. On June 15, 2020 we issued 3,000,000 shares of common stock, valued at $0.0017 each to one officer and one director of the Company under a Restricted Stock Award. On June 15, 2020, we issued 10,000,000 shares of common stock, valued at $0.0023 per share, to the medical officer for consulting services. On June 16, 2020, we issued 33,566,667 shares of common stock for the complete conversion of $40,280 for convertible note dated December 12, 2019. On June 22, 2020, we issued 13,634,482 shares of common stock, valued at $0.005 per share, for an investment in the Company’s Private Placement. On June 22, 2020, we issued 8,000,000 shares of common stock, valued at $0.0029 per share, for financing fees dated January 24, 2020. On June 25, 2020, we issued 10,000,000 shares of common stock, valued at $0.0083 per share, to the medical officer for consulting services. On June 29, 2020, we issued 344,827 shares of common stock, valued at $0.0029 per share, for an investment in the Company’s Private Placement. On June 29, 2020, we issued 2,200,000 shares of common stock, valued at $0.005 per share, for an investment in the Company’s Private Placement.

Note 9 - Subsequent Events

Note 9 - Subsequent Events	6 Months Ended
	Jun. 30, 2020
Notes
Note 9 - Subsequent Events	Note 9 – Subsequent Events On July 7, 2020, we issued 2,000,000 shares of common stock, valued at $0.0035 per share, for an investment in the Company’s Private Placement. On July 14, 2020, we issued 4,000,000 shares of common stock, valued at $0.005 per share, for an investment in the Company’s Private Placement. On July 17, 2020 we issued 7,500,000 shares of common stock, valued at $0.0064 each to two officers, and one director of the Company under a Restricted Stock Award. On July 17, 2020, we issued 2,000,000 shares of common stock, valued at $0.0064 per share, for consulting services. On July 23, 2020, we issued 3,448,275 shares of common stock, valued at $0.0029 per share, for an investment in the Company’s Private Placement. On July 31, 2020 we issued 12,000,000 shares of common stock, valued at .0077 each to three officers, and one director of the Company under a Restricted Stock Award. On August 4, 2020, we issued 8,969,230 shares of common stock for the complete conversion of $34,980 for convertible note dated February 4, 2020. In accordance with ASC 855, the Company has analyzed its operations subsequent to June 30, 2020 through the date these financial statements were issued, and has determined that it does not have any other material subsequent events to disclose in these financial statements.

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Notes
Note 10 - Commitments and Contingencies	Note 10 – Commitments and Contingencies Effective May 1, 2017, the Company entered into a fourth amendment to a Lease Agreement for property located in Oceanside, CA. On March 1, 2020, the Company entered into a fifth amendment to the lease agreement for property located in Oceanside, CA. The amendment extends the expiration date to April 20, 2023 with escalating monthly payments ranging from $2,024 to $2,153. The lease consists of approximately 1,700 square feet. Total rent expense for the six months. Future minimum lease payments as of June 30, 2020 are as follows: For the quarter ending June 30, 2021 $ 18,871 2022 25,572 2023 6,459

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies: Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2020
Policies
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission (SEC) Regulation S-X, and should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2019, included in the Company’s Annual Report on Form 10-K filed with the SEC on May 21, 2020. The accompanying unaudited condensed consolidated financial statements include the accounts of TSOI and its subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation. The unaudited condensed consolidated financial statements contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the balances and results for the interim period included herein. The results of operations for the three and six months ended June 30, 2020 and 2019 are not necessarily indicative of the results to be expected for the full year or any future interim periods. The accompanying condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated balance sheet at December 31, 2019, contained in the above referenced Form 10-K.

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies: Principles of Consolidation (Policies)	6 Months Ended
	Jun. 30, 2020
Policies
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of Therapeutic Solutions International, Inc. and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies: Revenue Recognition (Policies)	6 Months Ended
	Jun. 30, 2020
Policies
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 606, “Revenue from Contracts with Customers” (“ASC 606”). In accordance with ASC 606, the Company applies the following methodology to recognize revenue: 1) 2) 3) 4) 5) ASC 606 provides that sales revenue is recognized when control of the promised goods or services is transferred to customers at an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company generally satisfies performance obligations upon shipment of the product or service to the customer. This is consistent with the time in which the customer obtains control of the product or service.

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies: Cash and Cash Equivalents (Policies)	6 Months Ended
	Jun. 30, 2020
Policies
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies: Derivative Liabilities (Policies)	6 Months Ended
	Jun. 30, 2020
Policies
Derivative Liabilities	Derivative Liabilities A derivative is an instrument whose value is “derived” from an underlying instrument or index such as a future, forward, swap, option contract, or other financial instrument with similar characteristics, including certain derivative instruments embedded in other contracts and for hedging activities. As a matter of policy, the Company does not invest in separable financial derivatives or engage in hedging transactions. However, the Company entered into certain debt financing transactions in fiscal 2020 and 2019 as disclosed in Note 5, containing certain conversion features that have resulted in the instruments being deemed derivatives. We evaluate such derivative instruments to properly classify such instruments within equity or as liabilities in our financial statements. Our policy is to settle instruments indexed to our common shares on a first-in-first-out basis. The classification of a derivative instrument is reassessed at each reporting date. If the classification changes as a result of events during a reporting period, the instrument is reclassified as of the date of the event that caused the reclassification. There is no limit on the number of times a contract may be reclassified. Instruments classified as derivative liabilities are remeasured using the Black-Scholes model at each reporting period (or upon reclassification) and the change in fair value is recorded on our consolidated statement of operations. We recorded derivative liabilities of $187,968 and $521,700 at June 30, 2020 and December 31, 2019, respectively.

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies: Fair Value of Financial Instruments (Policies)	6 Months Ended
	Jun. 30, 2020
Policies
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, prepaids, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of June 30, 2020, the Company has level 3 fair value calculations on derivative liabilities. The table below reflects the results of our Level 3 fair value calculations: The following is the change in derivative liability for the six months ended June 30, 2020: Balance- December 31, 2019 $ 521,700 Issuance of new derivative liabilities 198,248 Conversions to paid-in capital (313,704) Change in fair market value of derivative liabilities (218,276) Balance- June 30, 2020 $ 187,968

Note 2 - Summary of Significa_8

Note 2 - Summary of Significant Accounting Policies: Use of Estimates (Policies)	6 Months Ended
	Jun. 30, 2020
Policies
Use of Estimates	Use of Estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Estimates were made relating to valuation allowances, impairment of assets, share-based compensation expense and accruals. Actual results could differ materially from those estimates.

Note 2 - Summary of Significa_9

Note 2 - Summary of Significant Accounting Policies: Net Income (Loss) Per Share (Policies)	6 Months Ended
	Jun. 30, 2020
Policies
Net Income (Loss) Per Share	Net Income (Loss) Per Share Basic income (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted income (loss) per share is computed similar to basic income (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were dilutive. In periods in which a net loss is incurred, basic and diluted loss per share are the same, and additional potential common shares are excluded as their effect would be antidilutive. For the periods ended June 30, 2020 and 2019, a total of 47,358,833 and 876,393,993, respectively, potential common shares, consisting of shares underlying outstanding convertible notes payable were excluded as their inclusion would be antidilutive due to the net loss during the period.

Note 2 - Summary of Signific_10

Note 2 - Summary of Significant Accounting Policies: Property and Equipment (Policies)	6 Months Ended
	Jun. 30, 2020
Policies
Property and Equipment	Property and Equipment Property and equipment are recorded at cost, less accumulated depreciation. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is calculated using the straight-line method over the term of the agreement. Depreciation expense for the six months ended June 30, 2020 and 2019 was $65 and $0, respectively.

Note 2 - Summary of Signific_11

Note 2 - Summary of Significant Accounting Policies: Intangible Assets (Policies)	6 Months Ended
	Jun. 30, 2020
Policies
Intangible Assets	Intangible Assets Intangible assets consisted primarily of intellectual properties such as proprietary nutraceutical formulations. Intellectual assets are capitalized in accordance with ASC Topic 350 “Intangibles – Goodwill and Other.” Intangible assets with finite lives are amortized over their respective estimated lives and reviewed for impairment whenever events or other changes in circumstances indicate that the carrying amount may not be recoverable. Amortization expense for the six months ended June 30, 2020 and 2019 was $3,296 and $0, respectively.

Note 2 - Summary of Signific_12

Note 2 - Summary of Significant Accounting Policies: Long-lived Assets (Policies)	6 Months Ended
	Jun. 30, 2020
Policies
Long-lived Assets	Long-lived Assets In accordance with ASC 360, Property, Plant and Equipment, the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value.

Note 2 - Summary of Signific_13

Note 2 - Summary of Significant Accounting Policies: Research and Development (Policies)	6 Months Ended
	Jun. 30, 2020
Policies
Research and Development	Research and Development Research and Development costs are expensed as incurred. Research and Development expenses were $329,772 and $6,232 for the six months ended June 30, 2020 and 2019, respectively.

Note 2 - Summary of Signific_14

Note 2 - Summary of Significant Accounting Policies: Income Taxes (Policies)	6 Months Ended
	Jun. 30, 2020
Policies
Income Taxes	Income Taxes The Company accounts for income taxes under ASC 740 "Income Taxes," which codified SFAS 109, "Accounting for Income Taxes" and FIN 48 “Accounting for Uncertainty in Income Taxes – an Interpretation of FASB Statement No. 109.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.

Note 2 - Summary of Signific_15

Note 2 - Summary of Significant Accounting Policies: Stock-Based Compensation (Policies)	6 Months Ended
	Jun. 30, 2020
Policies
Stock-Based Compensation	Stock-Based Compensation Compensation expense for stock issued to employees is determined as the fair value of consideration or services received or the fair value of the equity instruments issued, whichever is more reliably measured. The Financial Accounting Standards Board (FASB) issued ASU 2018-07 to expand the scope of Topic 718 to include share-based payments issued to nonemployees.

Note 2 - Summary of Signific_16

Note 2 - Summary of Significant Accounting Policies: Leases (Policies)	6 Months Ended
	Jun. 30, 2020
Policies
Leases	Leases In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. The Company recorded a Right-of-use asset of $65,384 and a Lease Liability of $65,384 as of June 30, 2020.

Note 2 - Summary of Signific_17

Note 2 - Summary of Significant Accounting Policies: Recent Accounting Pronouncements (Policies)	6 Months Ended
	Jun. 30, 2020
Policies
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2019, the FASB issued guidance that simplifies the accounting for income taxes by removing certain exceptions in existing guidance and improves consistency in application by clarifying and amending existing guidance. This guidance is effective for annual periods beginning after December 15, 2020, and interim periods within those annual periods, where the transition method varies depending upon the specific amendment. Early adoption is permitted, including adoption in any interim period. An entity that elects to early adopt the amendments in an interim period should reflect any adjustments as of the beginning of the annual period that includes that interim period, and all amendments must be adopted in the same period. The Company has reviewed the provisions of the new standard, but it is not expected to have a significant impact on the Company. In January 2020, the FASB issued Accounting Standards Update (“ASU”) No. 2020-01, "Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying the Interactions between Topic 321, Topic 323, and Topic 815", which clarifies the interaction of the accounting for equity securities under Topic 321 and investments accounted for under the equity method of accounting under Topic 323, and the accounting for certain forward contracts and purchased options accounted for under Topic 815. This guidance is effective for the Company for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Early adoption is permitted. The Company has reviewed the provisions of the new standard, but it is not expected to have a significant impact on the Company.

Note 2 - Summary of Signific_18

Note 2 - Summary of Significant Accounting Policies: Fair Value of Financial Instruments: Schedule of Change in derivative liability (Tables)	6 Months Ended
	Jun. 30, 2020
Tables/Schedules
Schedule of Change in derivative liability	Balance- December 31, 2019 $ 521,700 Issuance of new derivative liabilities 198,248 Conversions to paid-in capital (313,704) Change in fair market value of derivative liabilities (218,276) Balance- June 30, 2020 $ 187,968

Note 4 - Property and Equipme_2

Note 4 - Property and Equipment: Schedule of Fixed Assets (Tables)	6 Months Ended
	Jun. 30, 2020
Tables/Schedules
Schedule of Fixed Assets	June 30, 2020 December 31, 2019 Computer hardware $ 10,747 $ 10,747 Office furniture and equipment 9,087 3,639 Shipping and other equipment 1,575 1,575 Total 21,409 15,961 Accumulated depreciation (16,026) (15,961) Property and equipment, net $ 5,383 $ -

Note 5 - Other Assets_ Schedule

Note 5 - Other Assets: Schedule of Other Assets (Tables)	6 Months Ended
	Jun. 30, 2020
Tables/Schedules
Schedule of Other Assets	June 30, 2020 December 31, 2019 Prepaid consulting $ 3,792 $ 20,238 Deposit 4,123 4,123 Licenses, net 143,665 146,961 Total $ 151,580 $ 171,322

Note 5 - Other Assets_ Schedu_2

Note 5 - Other Assets: Schedule of prepaid consulting agreements (Tables)	6 Months Ended
	Jun. 30, 2020
Tables/Schedules
Schedule of prepaid consulting agreements	June 30, 2020 December 31, 2019 License $ 153,552 $ 153,552 Accumulated amortization (9,887) (6,591) Licenses, net $ 143,665 $ 146,961

Note 10 - Commitments and Con_2

Note 10 - Commitments and Contingencies: Schedule of Future Minimum Lease Payments (Tables)	6 Months Ended
	Jun. 30, 2020
Tables/Schedules
Schedule of Future Minimum Lease Payments	For the quarter ending June 30, 2021 $ 18,871 2022 25,572 2023 6,459

Note 1 - Organization and Bus_2

Note 1 - Organization and Business Description (Details)	6 Months Ended
	Jun. 30, 2020
Details
Entity Incorporation, Date of Incorporation	Aug. 6, 2007
Entity Information, Former Legal or Registered Name	Friendly Auto Dealers, Inc.

Note 2 - Summary of Signific_19

Note 2 - Summary of Significant Accounting Policies: Derivative Liabilities (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Details
Derivative Liability	$ 187,968	$ 521,700

Note 2 - Summary of Signific_20

Note 2 - Summary of Significant Accounting Policies: Fair Value of Financial Instruments: Schedule of Change in derivative liability (Details)	6 Months Ended
	Jun. 30, 2020USD ($)
Details
Derivative Liability, Current, Starting Balance	$ 521,700
Issuance of new derivative liabilities	198,248
Conversions to paid-in capital	(313,704)
Change in fair market value of derivative liabilities	(218,276)
Derivative Liability, Current, Ending Balance	$ 187,968

Note 2 - Summary of Signific_21

Note 2 - Summary of Significant Accounting Policies: Net Income (Loss) Per Share (Details) - shares	Jun. 30, 2019	Jun. 30, 2020
Details
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	876,393,993	47,358,833

Note 3 - Restricted Cash (Detai

Note 3 - Restricted Cash (Details)	6 Months Ended
	Jun. 30, 2020USD ($)
Details
Restricted Cash, Current	$ 10,000
Restricted Cash, Current, Nature of Restriction, Description	used as collateral for a Company credit card

Note 4 - Property and Equipme_3

Note 4 - Property and Equipment: Schedule of Fixed Assets (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Property, Plant and Equipment, Gross	$ 21,409	$ 15,961
Accumulated depreciation	(16,026)	(15,961)
Property and equipment, net	5,383	0
Computer Equipment
Property, Plant and Equipment, Gross	10,747	10,747
Office Equipment
Property, Plant and Equipment, Gross	9,087	3,639
Equipment
Property, Plant and Equipment, Gross	$ 1,575	$ 1,575

Note 5 - Other Assets_ Schedu_3

Note 5 - Other Assets: Schedule of Other Assets (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Details
Prepaid consulting	$ 3,792	$ 20,238
Deposit	4,123	4,123
Licenses, net	143,665	146,961
Assets, Noncurrent	$ 151,580	$ 171,322

Note 5 - Other Assets_ Schedu_4

Note 5 - Other Assets: Schedule of prepaid consulting agreements (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Details
License	$ 153,552	$ 153,552
Accumulated amortization	(9,887)	(6,591)
Licenses, net	$ 143,665	$ 146,961

Note 6 - Notes Payable-Relate_2

Note 6 - Notes Payable-Related Party (Details) - USD ($)	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019
Details
Long-term Debt, Description	unsecured interest-bearing demand notes
Long-term Debt	$ 954,611	$ 937,528
Accrued Interest	$ 13,341		$ 7,936

Note 7 - Convertible Notes Pa_2

Note 7 - Convertible Notes Payable: Convertible Promissory Notes (Details) - Convertible Notes Payable #1	6 Months Ended
	Jun. 30, 2020
Debt Instrument, Description	Company entered into one $33,000, one $28,000, and one $43,000 convertible promissory notes with a third party for which the proceeds were used for operations
Debt Instrument, Interest Rate, Stated Percentage	12.00%
Debt Instrument, Convertible, Terms of Conversion Feature	convertible to shares of the Company's common stock 180 days after issuance

Note 7 - Convertible Notes Pa_3

Note 7 - Convertible Notes Payable: Derivative liabilities (Details) - USD ($)	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Issuance of new derivative liabilities	$ 198,248
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	1 year
Derivative Liability	$ 187,968	$ 521,700
Conversion feature
Issuance of new derivative liabilities	$ 198,248
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used	Black-Scholes option pricing model
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	239.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	0.17%
Conversion feature | Minimum
Fair Value Assumptions, Conversion Price	$ 0.0008
Share Price	0.0023
Conversion feature | Maximum
Fair Value Assumptions, Conversion Price	0.0012
Share Price	$ 0.0033

Note 8 - Equity (Details)

Note 8 - Equity (Details) - $ / shares	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Common Stock, Shares Authorized	2,500,000,000	2,500,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Common Stock, Shares, Issued	1,947,438,492	1,614,627,811
Common Stock, Shares, Outstanding	1,947,438,492	1,614,627,811
Preferred Stock, Shares Outstanding	0
Preferred Stock, Shares Issued	0
Stock Transaction 1
Sale of Stock, Transaction Date	Mar. 2, 2020
Stock Issued During Period, Shares, New Issues	8,333,333
Stock Transaction 2
Sale of Stock, Transaction Date	Mar. 12, 2020
Stock Issued During Period, Shares, New Issues	11,764,706
Stock Transaction 3
Sale of Stock, Transaction Date	Mar. 26, 2020
Stock Issued During Period, Shares, New Issues	21,818,182
Stock Transaction 4
Sale of Stock, Transaction Date	May 29, 2020
Stock Issued During Period, Shares, New Issues	10,000,000
Stock Transaction 5
Sale of Stock, Transaction Date	Jun. 2, 2020
Stock Issued During Period, Shares, New Issues	12,500,000
Stock Transaction 6
Sale of Stock, Transaction Date	Jun. 3, 2020
Stock Issued During Period, Shares, New Issues	19,733,333
Stock Transaction 7
Sale of Stock, Transaction Date	Jun. 4, 2020
Stock Issued During Period, Shares, New Issues	24,733,333
Stock Transaction 8
Sale of Stock, Transaction Date	Jun. 4, 2020
Stock Issued During Period, Shares, New Issues	5,000,000
Stock Transaction 9
Sale of Stock, Transaction Date	Jun. 4, 2020
Stock Issued During Period, Shares, New Issues	70,000,000
Stock Transaction 10
Sale of Stock, Transaction Date	Jun. 8, 2020
Stock Issued During Period, Shares, New Issues	10,000,000
Stock Transaction 11
Sale of Stock, Transaction Date	Jun. 9, 2020
Stock Issued During Period, Shares, New Issues	18,181,818
Stock Transaction 12
Sale of Stock, Transaction Date	Jun. 11, 2020
Stock Issued During Period, Shares, New Issues	40,000,000
Stock Transaction 13
Sale of Stock, Transaction Date	Jun. 15, 2020
Stock Issued During Period, Shares, New Issues	3,000,000
Stock Transaction 14
Sale of Stock, Transaction Date	Jun. 15, 2020
Stock Issued During Period, Shares, New Issues	10,000,000
Stock Transaction 15
Sale of Stock, Transaction Date	Jun. 16, 2020
Stock Issued During Period, Shares, New Issues	33,566,667
Stock Transaction 16
Sale of Stock, Transaction Date	Jun. 22, 2020
Stock Issued During Period, Shares, New Issues	13,634,482
Stock Transaction 17
Sale of Stock, Transaction Date	Jun. 22, 2020
Stock Issued During Period, Shares, New Issues	8,000,000
Stock Transaction 18
Sale of Stock, Transaction Date	Jun. 25, 2020
Stock Issued During Period, Shares, New Issues	10,000,000
Stock Transaction 19
Sale of Stock, Transaction Date	Jun. 29, 2020
Stock Issued During Period, Shares, New Issues	344,827
Stock Transaction 20
Sale of Stock, Transaction Date	Jun. 29, 2020
Stock Issued During Period, Shares, New Issues	2,200,000

Note 9 - Subsequent Events (Det

Note 9 - Subsequent Events (Details)	6 Months Ended
	Jun. 30, 2020shares
Event 1
Sale of Stock, Transaction Date	Jul. 7, 2020
Stock Issued During Period, Shares, New Issues	2,000,000
Event 2
Sale of Stock, Transaction Date	Jul. 14, 2020
Stock Issued During Period, Shares, New Issues	4,000,000
Event 3
Sale of Stock, Transaction Date	Jul. 17, 2020
Stock Issued During Period, Shares, New Issues	7,500,000
Event 4
Sale of Stock, Transaction Date	Jul. 17, 2020
Stock Issued During Period, Shares, New Issues	2,000,000
Event 5
Sale of Stock, Transaction Date	Jul. 23, 2020
Stock Issued During Period, Shares, New Issues	3,448,275
Event 6
Sale of Stock, Transaction Date	Jul. 31, 2020
Stock Issued During Period, Shares, New Issues	12,000,000
Event 7
Sale of Stock, Transaction Date	Aug. 4, 2020
Stock Issued During Period, Shares, New Issues	8,969,230

Note 10 - Commitments and Con_3

Note 10 - Commitments and Contingencies: Schedule of Future Minimum Lease Payments (Details)	Jun. 30, 2020USD ($)
Details
2021	$ 18,871
2022	25,572
2023	$ 6,459